Short-term effect of intravitreal injection of ranibizumab (Lucentis) on intraocular pressure

Journal of Glaucoma

Volumn 18, Issue 9, 2009, Pages 658-661

  Gismondi, Maurizio ^a   Salati, Carlo ^a   Salvetat, Maria L ^a   Zeppieri, Marco ^a   Brusini, Paolo ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Age related macular degeneration; Intraocular pressure; Intravitreal injection; Lucentis; Ranibizumab

Indexed keywords

RANIBIZUMAB;

ADULT; ARTICLE; BIOMETRY; DRUG ADMINISTRATION ROUTE; ECHOGRAPHY; ENDOPHTHALMITIS; FEMALE; HUMAN; INTRAOCULAR PRESSURE; LENS DISEASE; MAJOR CLINICAL STUDY; MALE; PHAKIC INTRAOCULAR LENS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA ARTERY OCCLUSION; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA MACULA DEGENERATION; RETINA TEAR; ULTRASOUND; UVEITIS; VITREOUS HEMORRHAGE;

ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; LENS, CRYSTALLINE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSEUDOPHAKIA; TIME FACTORS; TONOMETRY, OCULAR; VITREOUS BODY; WET MACULAR DEGENERATION;

EID: 74549191872     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e31819c4893     Document Type: Article

References (26)

1. Klein R, Peto T, Bird A, et al. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004;137:486-495
2. Frank RN, Amin RH, Eliott D, et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol. 1996;122:393-403
3. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338-346
4. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol. 1999;293:865-881
5. Van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA. 2005;293:1509-1513
6. Rosenfeld PJ, Brown DM, Heier JS, et al, for the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431
7. Heier JS, Antoszk AN, Pavan PR, et al. Ranibizumab for treatment of age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006; 113:642
8. Rosenfeld PJ, Heier JS, Hantsbarger G, et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:623-632
9. Kourlas H, Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther. 2007;29:1850-1861
10. Pallikaris IG, Kymionis GD, Ginis HS, et al. Ocular rigidity in living human eyes. Invest Ophthalmol Vis Sci. 2005;46:409-414
11. Kotliar K, Maier M, Bauer S, et al. Effect of intravitreal injections and volume changes on intraocular pressure: clinical and biomechanical model. Acta Ophthalmol Scand. 2007;85: 777-781
12. Brown DM, Kaiser PK, Michels M, et al, for the ANCHOR Study Group. Ranibizumab versus verteporforin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355:1432-1444
13. Mojica G, Hariprasad SM, Jager RD, et al. Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. Br J Ophthalmol. 2008;92:584
14. Frenkel RP, Hong J, Shin DH. Comparison of the Tono-Pen to the Goldmann applanation tonometer. Arch Ophthalmol. 1988;106:750-753
15. Morlet N, Young SH. Prevention of intraocular pressure rise following intravitreal injection. Br J Ophthalmol. 1993;77: 572-573
16. Cioffi G, Granstam E, Alm A. Ocular circulation. In: Kaufman P, Alm A, eds. Adler's Physiology of the Eye. 10th ed. St Louis: Mosby; 2003:747-784
17. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24 (suppl):S3-S19
18. Hayreh SS, Jonas JB. Optic disc and retinal nerve fibre layer damage after transient central retinal artery occlusion: an experimental study in rhesus monkeys. Am J Ophthalmol. 2000; 129:786-795
19. Brubaker RF. Targeting outflow facility in glaucoma management. Surv Ophthalmol. 2003;48 (suppl):S17-S20
20. Benz MS, Albini TA, Holz ER, et al. Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology. 2006;113:1174-1178
21. Brubaker RF. Clinical measurements of aqueous humour dynamics: implications for addressing glaucoma. In: Civa MM, ed. The Eye's Aqueous Humor: From Secretion to Glaucoma. San Diego: Academic Press; 1998:234-284
22. Iester M, Mermoud A, Achache F, et al. New TonoPen XL: comparison with the Goldmann tonometer. Eye. 2001;15: 52-58
23. Kothe AC. The effect of posture on intraocular pressure and pulsatile ocular blood flow in normal and glaucomatous eyes. Surv Ophthalmol. 1994;38 (suppl 1):S191-S197
24. Cho YK. Early intraocular pressure and anterior chamber depth changes after phacoemulsification and intraocular lens implantation in nonglaucomatous eyes: comparison of groups stratified by axial length. J Cataract Refract Surg. 2008;34: 1104-1109
25. Frenkel RE, Mani L, Toler AR, et al. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol. 2007;143:1034-1035
26. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina. 2007;27:1044-1047